Levonic-Opto (Levofloxacin)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By binding to these targets, the drug prevents bacterial DNA supercoiling and separation, leading to bactericidal activity against a broad spectrum of Gram‑positive and Gram‑negative ocular pathogens.

The dosing regimen for Levonic‑Opto is determined by the prescribing clinician based on the specific infection, severity and patient factors. The prescriber will specify the number of drops, frequency and duration of therapy in the prescription.

Safety of levofloxacin ophthalmic use during pregnancy or lactation has not been established. The potential benefits must be weighed against possible risks, and the decision should be made by a qualified healthcare professional in consultation with the patient.

To order Levonic‑Opto, submit an enquiry on the product page at gnhindia.com, providing the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levonics‑Opto (levofloxacin) belongs to the fluoroquinolone class, offering broad‑spectrum coverage and high ocular penetration. Compared with older agents such as ciprofloxacin, levofloxacin provides a lower dosing frequency and may be more effective against resistant strains. Alternatives like moxifloxacin or fortified vancomycin are used for specific resistant organisms or severe infections.

Levonics‑Opto should be stored at room temperature below 25 °C, in its original packaging, protected from light and moisture. Do not freeze the product. Ensure the container is tightly closed when not in use to maintain sterility.

The product is applied as eye drops directly onto the affected eye(s). The prescribed number of drops is instilled at the recommended interval, typically without touching the tip of the bottle to the ocular surface. Patients should wash their hands before and after application.

Serious risks include severe allergic reactions (e.g., swelling, rash, Stevens‑Johnson syndrome), corneal edema, sudden loss of visual acuity, and rare systemic effects such as tendon toxicity if systemic absorption occurs. Patients should seek immediate medical attention if they experience intense pain, vision changes or signs of an allergic reaction.

Levonics‑Opto should be avoided in individuals with a known hypersensitivity to levofloxacin or any fluoroquinolone. Caution is also advised for patients with compromised corneal integrity, those using contact lenses during therapy, and patients receiving systemic quinolones due to increased risk of tendon-related adverse events.